BCMA 1-R2 CAR-Ts were the safe “off the shelf” CAR T-cells and preserved their phenotype and potency after scale-up manufacturing, supporting a promising clinical evaluation in progressive MM patients. Here, TNFRSF17 is linked to Miyoshi myopathy.